CXCL13 and melanoma: Studies have shown that the presence of CXCL13+ CD4+ T cells and CXCL13 expression broadly correlates with OS in a cohort of melanoma patients, independent of immunotherapy type (Litchfield et al., 2021; Veatch et al., 2022).